中山大学肿瘤防治中心 副主任医师
擅长: 白血病、淋巴瘤、多发性骨髓瘤和骨髓增生异常综合征诊断与治疗
简介: 医疗专长: 擅长淋巴瘤、骨髓瘤、白血病及MDS的诊治及靶向治疗主要研究方向: 新的血液肿瘤临床诊断和治疗方法研究 肿瘤转移治疗及预防的研究 肿瘤分子诊断及基因靶向和免疫生物治疗研究 社会兼职: 广东省抗癌协会姑息专业委员会青年委员; 美国血液病学协会会员学术研究成果: 近5年以第一作者发表血液病相关SCI 30余篇,主持国自然基金1项,省卫生厅基金1项,中山大学青年教师培育项目、中山大学肿瘤防治中心优秀青年人才项目、中山大学肿瘤防治中心临床医学科学家项目各一项 主要学术论文: 1. Wang L, Hua Wang, Jing-hua Wang, Zhong-jun Xia, Yue Lu,Hui-qiang Huang, Wen-qi Jiang, Yu-jing Zhang. Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase. Oncotarget. 2015 Oct 6;6(30):30317-26. (SCI: 6.359) 2. Wang L, Hua Wang, Hao Chen, Wei-da Wang, Xiao-qin Chen, Qi-rong Geng, Zhong-jun Xia, Yue Lu. Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma. Oncotarget. 2015, early online (SCI: 6.359) 3. Wang L, Wang ZH, Chen XQ, Li YJ, Wang KF, Xia YF, Xia ZJ. First-line combination of gemcitabine, oxaliplatin, and l-asparaginase (gelox) followed by involved-field radiation therapy for patients with stage ie/iie extranodal natural killer/t-cell lymphoma. Cancer. 2013;119:348-355. (SCI: 5.201) 4. Liang Y, Wang L(共同第一), Zhu Y, Lin Y, Liu H, Rao H, Xu G, Rong T: Primary pulmonary lymphoepithelioma-like carcinoma: Fifty-two patients with long-term follow-up. Cancer. 2012;118:4748-4758. (SCI: 5.201) 5. Wang L, Lin Y, Long H, Liu H, Rao H, He Y, Rong T, Liang Y. Esophageal carcinosarcoma: A unique entity with better prognosis. Annals of surgical oncology. 2013;20:997-1004. (SCI: 4.12) 6. Wang L, Wang JH, Wu-Xiao ZJ, Xia ZJ, Huang HQ, Lu Y. Lymphopenia during routine follow-up may predict relapse in patients with extranodal nk/t cell lymphoma. Tumour biology. 2015;36:1747-1753. (SCI: 3.611) 7. Wang L, Xia ZJ, Zhang YJ, Huang HQ, Lin TY, Lu Y. Radical surgery may be not an optimal treatment approach for pulmonary malt lymphoma. Tumour biology. 2015 Aug;36(8):6409-16 (SCI: 3.611) 8. Wang L, Wang Z, Xia ZJ, Lu Y, Huang HQ, Zhang YJ. CD56-negative extranodal NK/T cell lymphoma should be regarded as a distinct subtype with poor prognosis. Tumour Biol. 2015 Sep;36(10):7717-23. (SCI: 3.611) 9. Wang L, Chi PD, Chen H, Xiang J, Xia ZJ, Zhang YJ. Low level of high-density lipoprotein cholesterol correlates with poor prognosis in extranodal natural killer/t cell lymphoma. Tumour biology. 2014;35:2141-2149. (SCI: 3.611) 10. Wang L, Lin GN, Jiang XL, Lu Y: Expression of ezrin correlates with poor prognosis of nasopharyngeal carcinoma. Tumour biology. 2011;32:707-712. (SCI: 3.611) 11. Wang L, Long W, Li PF, Lin YB, Liang Y. An Elevated Peripheral Blood Monocyte-to-Lymphocyte Ratio Predicts Poor Prognosis in Patients with Primary Pulmonary Lymphoepithelioma-Like Carcinoma. PLoS One. 2015 May 7;10(5):e0126269. (SCI: 3.234) 12. Wang L, Xia ZJ, Lu Y, Wang QX, Niu SQ, Huang HQ, Zhang YJ. A modified international prognostic index including pretreatment hemoglobin level for early stage extranodal natural killer/t cell lymphoma. Leukemia & lymphoma. 2015:1-7 (SCI: 2.891) 13. Wang L, Wu-Xiao ZJ, Chen XQ, Zhang YJ, Lu Y, Xia ZJ. Hepatitis b virus infection correlates with poor prognosis of extranodal natural killer/t cell lymphoma. Leukemia & lymphoma. 2015 Apr;56(4):936-41. (SCI: 2.891) 14. Wang L, Liu P, Geng Q, Chen X, Lv Y. Prognostic significance of neuron-specific enolase in patients with diffuse large b-cell lymphoma treated with rituximab-based immunochemotherapy. Leukemia & lymphoma. 2011;52:1697-1703. (SCI: 2.891) 15. Wang L, Xia ZJ: Combination of albumin-bound paclitaxel and pegylated liposomal doxorubicin is effective in treatment of heavily treated relapsed/refractory diffuse large b-cell lymphoma: A case report. Leukemia & lymphoma. 2013;54:2553-2555. (SCI: 2.891) 16. Zhang W, Wang L(共同第一), Zhou D, Cui Q, Zhao D, Wu Y: Expression of tumor-associated macrophages and vascular endothelial growth factor correlates with poor prognosis of peripheral t-cell lymphoma, not otherwise specified. Leukemia & lymphoma. 2011;52:46-52. (SCI: 2.891) 17. Wang L, Wang H, Li PF, Lu Y, Xia ZJ, Huang HQ, Zhang YJ. CD38 expression predicts poor prognosis and might be a potential therapy target in extranodal nk/t cell lymphoma, nasal type. Annals of hematology. 2015 Aug;94(8):1381-8. (SCI: 2.634) 18. Wang L, Wang H, Xia ZJ, Huang HQ, Jiang WQ, Lin TY, Lu Y. Peripheral blood lymphocyte to monocyte ratio identifies high-risk adult patients with sporadic Burkitt lymphoma. Annals of hematology. 2015 Oct;94(10):1645-54. (SCI: 2.634) 19. Wang L, Xia ZJ, Lu Y, Zhang YJ. Prophylactic cervical lymph node irradiation provides no benefit for patients of stage ie extranodal natural killer/t cell lymphoma, nasal type. Medical oncology. 2015;32:320.(SCI: 2.634) 20. Wang L, Liao DZ, Zhang J, Xia ZJ, Peng XW, Lu Y: Clinical significance of serum soluble interleukin-2 receptor-alpha in extranodal natural killer/t-cell lymphoma (enktl): A predictive biomarker for treatment efficacy and valuable prognostic factor. Medical oncology. 2013;30:723. (SCI: 2.634) 21. Wang L, Wang WD, Xia ZJ, Zhang YJ, Xiang J, Lu Y: Combination of gemcitabine, l-asparaginase, and oxaliplatin (gelox) is superior to epoch or chop in the treatment of patients with stage ie/iie extranodal natural killer/t cell lymphoma: A retrospective study in a cohort of 227 patients with long-term follow-up. Medical oncology. 2014;31:860. (SCI: 2.634) 22. Wang L, Liu P, Chen X, Geng Q, Lu Y. Serum neuron-specific enolase is correlated with clinical outcome of patients with non-germinal center b cell-like subtype of diffuse large b-cell lymphoma treated with rituximab-based immunochemotherapy. Medical oncology. 2012;29:2153-2158. (SCI: 2.634) 23. Wang H, Li P, Wang L(通讯), Xia Z, Huang H, Lu Y, Li Z.High numbers of CD68+ tumor-associated macrophages correlate with poor prognosis in extranodal NK/T-cell lymphoma, nasal type. Ann Hematol. 2015 Sep;94(9):1535-44. (SCI: 2.634) 24. Wang L, Wang KF, Chang BY, Chen XQ, Xia ZJ. Once-weekly subcutaneous administration of bortezomib in patients with multiple myeloma. Asian Pac J Cancer Prev. 2015;16(5):2093-8. (SCI:2.514) 25. Jiang L, Wang L(共同第一), Li PF, Zhang XK, Chen JW, Qiu HJ, Wu XD, Zhang B. Positive expression of programmed death ligand-1 correlates with superior outcomes and might be a therapeutic target in primary pulmonary lymphoepithelioma-like carcinoma. Onco Targets Ther. 2015 Jun 15;8:1451-7. (SCI: 2.311) 26. Hua Wang, Wang L(共同第一), ZhiJun Wuxiao, HuiQiang Huang, WenQi Jiang, ZhiMing Li, Yue Lu, ZhongJun Xia. Increased serum levels of interleukin-10 predict poor prognosis in extranodal natural killer/T-cell lymphoma patients receiving asparaginase-based chemotherapy. OncoTargets and Therapy. 2015:8 2589–2599 (SCI: 2.311) 27. Wang L, Yongbin Lin, Qingqing Cai, Hao Long, Yu Zhang, Tiehua Rong, Guowei Ma, Ying Liang. Detection of rearrangement of anaplastic lymphoma kinase (ALK) and mutation of epidermal growth factor receptor (EGFR) in primary pulmonary lymphoepithelioma-like carcinoma. J Thorac Dis. 2015;7(9):1556-1562 (SCI: 1.783) 28. Wang L, Xia ZJ, Huang HQ, Lu Y, Zhang YJ: Cyclophosphamide, doxorubicin, vincristine, and prednisone (chop) in the treatment of stage ie/iie extranodal natural killer/t cell lymphoma, nasal type: 13-year follow-up in 135 patients. International journal of hematology. 2012;96:617-623. (SCI: 1.918) 29. Wang L, ZHI-HUI WANG, XIAO-QIN CHEN, KE-FENG WANG, HUI-QIANG HUANG and ZHONG-JUN XIA. First-line combination of GELOX followed by radiation therapy for patients with stage IE/IIE ENKTL: An updated analysis with long-term follow-up ONCOLOGY LETTERS.2015,10: 1036-1040(SCI: 1.554)
第一执业
广东罗浮山国药股份有限公司是一家从事药品生产,药品经营,中草药收购等业务的公司,成立于2008年12月24日,公司坐落在广东省,详细地址为:惠州市博罗县长宁镇广汕公路边岭排工业区(罗浮山药业城);经国
北京韩美药品有限公司(以下简称北京韩美)成立于1996年3月,公司产品业务涉及儿科产品、消化科产品、骨科产品、抗感染药等领域,98%的产品在国内成产,主要产品有妈咪爱、易坦静、易安平、美常安、利动、
益普生集团作为一家有着八十多年制药经验的欧洲制药集团,拥有20余种上市产品及遍布全球近4000名的员工。公司的发展战略是以三大治疗领域内的高科技产品为基础,即肿瘤、内分泌、神经肌肉类疾病,这些高
北京同仁堂股份有限公司同仁堂制药厂成立于1990年11月21日,注册地位于北京市大兴区中关村科技园区大兴生物医药产业基地天贵大街33号,法定代表人为张朝华。经营范围包括加工、制造中成药;出租办公用房
辉瑞在中国业务覆盖全国300余个城市,并在华上市了五大领域的高品质的创新药物,包括肿瘤、疫苗、抗感染、炎症与免疫、罕见病等多个领域的处方药和疫苗。多年来,辉瑞始终致力于“成为中国医疗卫生体系重要组成
石家庄以岭药业股份有限公司于1992年6月16日创建,公司以“继承创新、造福人类”为企业宗旨,以“科技健康明天”为企业发展目标,以健康人类为己任,造福社会为弘愿,始终坚持市场龙头、科技驱动的创新发展
北京同仁堂科技发展股份有限公司制药厂成立于1980年07月31日,注册地位于北京市丰台区南三环中路20号,法定代表人为王煜炜。经营范围包括制造胶剂、口服液、丸剂、颗粒剂、糖浆剂、擦剂、气雾剂、软胶囊
海南碧凯药业有限公司成立于1993年。是【国家高新技术企业】、国家工商总局【守合同重信誉单位】、海口工业【十佳企业】。拥有各类人才,员工近2000人。生产基地位于海口药谷,占地134亩,建筑面积10